medpagetoday.com/reading-ro...
Here is the Expert Critique from Keith Michael Giles, PhD
This study addresses an important question in the management of melanoma brain metastases (MBM): is there clinical benefit to adjuvant whole-brain radiation therapy (WBRT) following local treatment of MBMs? While previous randomized studies suggested that adjuvant WBRT may improve disease control, they did not demonstrate a survival benefit for this treatment approach, which may also impair cognitive function and quality of life. Importantly, this multicenter randomized phase III trial -- focusing solely on MBM patients -- shows that adjuvant WBRT does not produce significant clinical benefit: it does not lower the risk of distant intracranial failure at 12 months, nor does it improve overall survival or performance status of patients.
How can this study impact clinical practice? First, its findings provide crucial evidence to resolve the debate as to whether adjuvant WBRT should be offered after local treatment of MBMs. Second, other adjuvant therapies for MBMs that are in clinical development -- such as small-molecule inhibitors of the mitogen-activated protein kinase (MAPK) pathway or monoclonal antibodies that block immune checkpoints -- could represent a better approach than WBRT. These agents have been shown to be active within the central nervous system, where they may also produce fewer side effects than WBRT. Furthermore, research suggests there may be synergy between radiation and targeted therapy or immunotherapy, although it is not yet clear how best to combine these treatments for MBMs.
Peace,
Missy
